Dahaner Catapults into Major Bioprocessing Territory with $21 Billion Purchase of GE Life Science, an Industrial Info Market Brief

---

The $21 billion that Danaher paid to snap up GE Health Care/Life Sciences, while not the biggest Pharmaceutical & Biotech industry deal, may prove to be one of the most profitable in this era of COVID-19. Now rebranded as Cytiva, the new business' key attraction is its KUBio flexible, prefabricated cGMP biomanufacturing environment, offering configurable production lines. Its integrated production platform, known as the FlexFactory, featuring single-use systems throughout, with the modular units can be up and running more quickly than traditional plants. With the race on to develop an effective vaccine to COVID-19, a FlexFactory can be up and running within 18 months. producing vaccines and other biologicals.